General Information of Drug (ID: DMCP5U8)

Drug Name
5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline Drug Info
Synonyms CHEMBL293122; dihydroquinoline 31; BDBM10027; ZINC13808192; 5-[2-(Imidazol-1-yl)ethyl]-7,8-dihydroquinoline; 5-[2-(1H-imidazol-1-yl)ethyl]-7,8-dihydroquinoline
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10561174
TTD Drug ID
DMCP5U8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [2]
Naproxen DMZ5RGV Bursitis Approved [3]
Mesalazine DMOL5IU Diverticulitis Approved [4]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [5]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [6]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [7]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [8]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [7]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [9]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [11]
Naproxen DMZ5RGV Bursitis Approved [3]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [12]
Indomethacin DMSC4A7 Bursitis Approved [7]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [13]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [14]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [15]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [16]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [5]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PYRIDINE DMF8CJ9 N. A. N. A. Phase 4 [17]
NM-702 DMDJLY9 Angina pectoris BA40 Phase 3 [18]
E-6700 DMUWJI4 Asthma CA23 Phase 2 [19]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [20]
EV-077 DM1FCDH Type-2 diabetes 5A11 Phase 2 [21]
G-619 DM3H6YC Thrombosis DB61-GB90 Phase 1 [22]
NV-52 DM0UOA9 Inflammatory bowel disease DD72 Phase 1 [23]
Satigrel DM4LSJ2 Thrombosis DB61-GB90 Discontinued in Preregistration [24]
MILACAINIDE TARTRATE DMJLNUD Cardiac arrhythmias BC9Z Discontinued in Phase 2 [25]
Imitrodast DMQ2ULV Asthma CA23 Discontinued in Phase 2 [26]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [1]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [1]
Thromboxane-A synthase (TBXAS1) TTKNWZ4 THAS_HUMAN Inhibitor [1]

References

1 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51.
2 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
3 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
6 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
9 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
10 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
11 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
12 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
13 Pfizer. Product Development Pipeline. March 31 2009.
14 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
15 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
16 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
17 Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
18 The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
19 Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
20 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
21 Company report (Pharmaceuticalintelligence)
22 G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
23 Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
24 Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
25 Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
26 RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.